What we are studying
We are attempting to better understand the causes of myeloproliferative neoplasms (MPN) and to develop improved methods for the diagnosis and treatment of these diseases. These syndromes carry a high risk of developing leukemia. It is important to continue learning more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments. It is our belief that further basic knowledge about these cancer cells, as well as the effects of treatment, will lead to the improvement of current therapies and the development of entirely new treatments for these diseases. We are hoping to determine if a number of laboratory tests (biomarkers) will allow us to predict if future patients will respond to the treatment you are receiving.